Pisa Syndrome Most Likely in Parkinson’s Patients with Axial Symptoms and Sleep Disorder, Study Says
People with Parkinson’s disease are more likely to develop a disabling postural deformity known as Pisa syndrome if they have…
Articles by Marisa Wexler, MS
More Years of Schooling Linked to Better Response to DBS in Small Study
The more years of formal education that people with Parkinson’s disease have, the better they seem to respond to deep-brain…
Safety and Efficacy of Oral Cannabidiol in Treating Parkinson’s Psychosis Focus of Phase 2 Study in UK
A planned Phase 2 clinical trial will assess the safety and effectiveness of pharmaceutical-grade cannabidiol (CBD) in treating Parkinson’s-related…
$20M Grant Awarded for Research into Imaging Protein Misfolding in Parkinson’s
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a five-year, $20 million grant to researchers looking…
Review Highlights Sex-related Differences In Parkinson’s
Parkinson’s disease (PD) is more common among males, but it tends to progress faster in females. This and other…
Wearable Sensors Offer Way of Ably Monitoring Day-to-Day Movement in Parkinson’s Patients, Study Says
Electronically monitoring Parkinson’s symptoms as people go about their day is a feasible way of collecting clinically relevant data, a…
$2.8M NIH Grant Targets Proteins Involved in Brain Disorders
The National Institute of Neurological Disorders and Stroke, of the National Institute of Health (NIH), has awarded…
FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for Fibromyalgia
The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol…
Study Finds High Rate Of Sleep Disorders In Ethiopian Parkinson’s Patients
Trouble sleeping is incredibly frequent among people with Parkinson’s disease in Ethiopia, a new study suggests. Titled “…
Phase 3 Trial to Test Continuous Pump Delivery of Levodopa in Treating Motor Fluctuations
A new Phase 3 clinical trial, called the “BouNDless study,” will soon compare continuous administration of ND0612 to oral immediate-release…